JNJ - Johnson & Johnson Stock Price, Fair Value and News

149.33USD-0.59 (-0.39%)Market Closed

Market Summary

USD149.33-0.59

Market Closed

-0.39%

JNJ Alerts

Big jump in Earnings (Y/Y)

JNJ Stock Price

View Fullscreen

JNJ RSI Chart

JNJ Valuation

Market Cap

360.8B

Price/Earnings (Trailing)

9.38

Price/Sales (Trailing)

4.21

EV/EBITDA

12.75

Price/Free Cashflow

19.29

JNJ Price/Sales (Trailing)

JNJ Profitability

EBT Margin

23.42%

Return on Equity

54.95%

Return on Assets

22.37%

Free Cashflow Yield

5.18%

JNJ Fundamentals

JNJ Revenue

Revenue (TTM)

85.6B

Rev. Growth (Yr)

2.34%

Rev. Growth (Qtr)

-0.06%

JNJ Earnings

Earnings (TTM)

38.5B

Earnings Growth (Yr)

4.9K%

Earnings Growth (Qtr)

-19.61%

Breaking Down JNJ Revenue

52 Week Range

147.87175.97

(Low)(High)

Last 7 days

2.1%

Last 30 days

-4.9%

Last 90 days

-4.3%

Trailing 12 Months

-7.9%

How does JNJ drawdown profile look like?

JNJ Financial Health

Current Ratio

1.17

Debt/Equity

0.36

Debt/Cashflow

0.92

JNJ Investor Care

Dividend Yield

3.17%

Dividend/Share (TTM)

4.76

Buy Backs (1Y)

7.39%

Diluted EPS (TTM)

15.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	85.6B	0	0	0
2023	81.0B	82.3B	83.7B	85.2B
2022	76.3B	73.2B	69.8B	80.0B
2021	84.2B	89.2B	91.4B	78.7B
2020	82.7B	80.5B	80.9B	82.6B
2019	81.6B	81.3B	81.7B	82.1B
2018	78.7B	80.7B	81.4B	81.6B
2017	72.2B	72.5B	74.4B	76.5B
2016	70.2B	70.9B	71.6B	71.9B
2015	73.6B	71.9B	70.5B	70.1B
2014	71.9B	73.5B	74.4B	74.3B
2013	68.6B	70.0B	70.5B	71.3B
2012	65.0B	64.9B	65.9B	67.2B
2011	62.1B	63.4B	64.4B	65.0B
2010	62.5B	62.6B	62.5B	61.6B
2009	62.6B	61.4B	60.5B	61.9B
2008	0	62.0B	62.9B	63.7B
2007	0	0	0	61.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Johnson & Johnson

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	broadhurst vanessa	sold	-1,441,760	162	-8,891	evp, global corp affairs
Feb 13, 2024	duato joaquin	sold (taxes)	-237,880	157	-1,507	ceo and chairman of the board
Feb 13, 2024	wolk joseph j	acquired	-	-	1,780	exec vp, cfo
Feb 13, 2024	broadhurst vanessa	acquired	-	-	408	evp, global corp affairs
Feb 13, 2024	hait william	acquired	-	-	834	see remarks
Feb 13, 2024	swanson james d.	sold (taxes)	-30,780	157	-195	evp, cio
Feb 13, 2024	broadhurst vanessa	sold (taxes)	-32,990	157	-209	evp, global corp affairs
Feb 13, 2024	forminard elizabeth	acquired	-	-	651	executive vp, general counsel
Feb 13, 2024	decker robert j	sold (taxes)	-13,575	157	-86.00	vp corporate controller
Feb 13, 2024	fasolo peter	sold (taxes)	-74,820	157	-474	exec vp, chief hr officer

Which funds bought or sold JNJ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Horan Capital Advisors, LLC.	reduced	-0.34	16,730	2,894,740	1.03%
May 01, 2024	Wakefield Asset Management LLLP	sold off	-100	-1,659,250	-	-%
May 01, 2024	Ascent Wealth Partners, LLC	reduced	-83.76	-2,755,080	540,219	0.08%
May 01, 2024	HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC	reduced	-0.71	18,000	8,167,000	1.37%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	added	10.96	6,645,400	86,264,700	0.19%
May 01, 2024	Janney Capital Management LLC	reduced	-32.29	-7,484,000	16,152,000	1.07%
May 01, 2024	HUSSMAN STRATEGIC ADVISORS, INC.	added	140	2,340,620	3,986,390	0.93%
May 01, 2024	CAPSTONE INVESTMENT ADVISORS, LLC	added	14.44	779,244	5,806,680	0.02%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	added	80.38	168,418,000	373,679,000	0.33%
May 01, 2024	Kinsale Capital Group, Inc.	added	20.93	855,310	4,733,620	1.87%

Are Funds Buying or Selling JNJ?

Are funds buying JNJ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JNJ

No. of Funds

JNJ Alerts

Big jump in Earnings (Y/Y)

Unveiling Johnson & Johnson's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.53%	229,372,559	SC 13G/A
Jan 30, 2024	state street corp	5.52%	132,996,283	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	186,308,341	SC 13G/A
Feb 10, 2023	state street corp	5.45%	142,447,944	SC 13G/A
Feb 09, 2023	vanguard group inc	9.44%	246,826,621	SC 13G/A
Jan 31, 2023	blackrock inc.	7.6%	198,802,769	SC 13G/A
Feb 14, 2022	state street corp	5.51%	144,996,127	SC 13G/A
Feb 10, 2022	vanguard group inc	8.92%	234,782,632	SC 13G/A
Feb 01, 2022	blackrock inc.	7.6%	200,021,352	SC 13G/A
Feb 12, 2021	state street corp	5.47%	144,029,634	SC 13G

Recent SEC filings of Johnson & Johnson

View All Filings

Date Filed	Form Type	Document
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading

Peers (Alternatives to Johnson & Johnson)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	360.8B	85.6B	-4.95%	-7.94%	9.38	4.21	5.68%	202.39%
MRK	324.7B	60.1B	-1.63%	8.46%	889.69	5.4	1.40%	-97.49%
PFE	156.4B	46.5B	0.51%	-27.98%	-112.61	3.36	42.59%	-114.62%
AMGN	149.2B	28.2B	0.79%	21.40%	22.21	5.29	7.09%	2.52%
GILD	81.4B	27.1B	-9.38%	-17.77%	14.37	3	-0.60%	23.36%
TEVA	15.7B	15.8B	1.44%	59.77%	-27.34	0.99	6.17%	76.47%
MID-CAP
PRGO	4.5B	4.7B	5.59%	-11.79%	-352.77	0.96	4.58%	90.97%
ALKS	4.0B	1.7B	-10.87%	-16.72%	9.29	2.34	54.01%	364.56%
BHC	3.0B	9.0B	-20.59%	9.46%	-6.52	0.33	10.01%	-27.45%
AMPH	2.1B	644.4M	0.80%	17.68%	14.92	3.18	29.14%	50.51%
SMALL-CAP
TLRY	1.6B	743.2M	-16.18%	-15.48%	-4.44	2.1	24.65%	80.36%
TXMD	21.8M	1.3M	-16.00%	-50.65%	-2.12	16.74	-98.14%	-109.18%
ACRX	17.1M	-	2.02%	57.81%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	48.15%	-93.36%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-94.70%	-92.62%	0	0.01	-0.79%	-283.60%

Johnson & Johnson News

Latest updates

Johnson & Johnson Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.1%	21,383	21,395	21,351	21,519	20,894	19,939	19,996	20,215	19,840	9,769	23,338	23,312	22,321	22,475	21,082	18,336	20,691	20,747	20,729	20,562	20,021
Gross Profit	1.9%	14,872	14,597	14,745	15,057	14,207	13,855	13,824	13,893	13,822	8,267	16,088	15,725	15,258	14,661	14,110	11,757	13,629	13,613	13,862	13,622	13,406
S&GA Expenses	15.3%	5,257	4,560	5,400	6,665	6,138	4,223	4,975	6,226	5,938	2,613	6,000	6,073	5,432	6,457	5,431	4,993	5,203	6,039	5,374	5,546	5,219
EBITDA Margin	20.2%	0.33*	0.27*	0.27*	0.27*	0.25*	0.33*	0.34*	0.31*	0.32*	0.34*	0.30*	0.31*	-	-	-	-	-	-	-	-	-
Interest Expenses	82.4%	155	85.00	192	346	215	177	51.00	38.00	10.00	60.00	20.00	40.00	63.00	87.00	44.00	45.00	25.00	85.00	48.00	83.00	102
Income Taxes	60.2%	459	287	908	1,618	-669	501	862	1,026	713	-421	182	384	1,232	-91.00	847	314	713	208	-106	1,434	673
Earnings Before Taxes	-23.0%	3,714	4,826	5,217	6,306	-1,287	3,840	5,172	5,144	5,203	1,238	3,849	6,662	7,429	1,647	4,401	3,940	6,509	4,218	1,647	7,041	4,422
EBT Margin	32.4%	0.23*	0.18*	0.17*	0.17*	0.16*	0.24*	0.24*	0.21*	0.22*	0.24*	0.21*	0.23*	-	-	-	-	-	-	-	-	-
Net Income	-19.6%	3,255	4,049	26,028	5,144	-68.00	3,520	4,458	4,814	5,149	4,736	3,667	6,278	6,197	1,738	3,554	3,626	5,796	4,010	1,753	5,607	3,749
Net Income Margin	8.8%	0.45*	0.41*	0.41*	0.16*	0.16*	0.22*	0.27*	0.25*	0.26*	0.27*	0.20*	0.20*	-	-	-	-	-	-	-	-	-
Free Cashflow	-54.6%	2,850	6,274	6,522	3,058	2,394	3,763	5,332	4,718	3,372	4,317	7,543	4,501	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.6%	171,966	167,558	166,061	191,686	195,969	187,378	175,124	177,724	178,355	182,018	179,228	176,440	172,557	174,894	170,693	158,380	155,017	157,728	155,521	155,117	150,027
Current Assets	6.6%	57,002	53,495	53,703	60,567	64,388	55,294	65,236	63,847	60,424	60,979	59,889	53,769	52,533	51,237	57,578	45,892	44,226	45,274	44,333	41,799	41,987
Cash Equivalents	16.5%	25,473	21,859	19,728	21,183	19,170	12,889	11,355	10,983	10,463	14,487	17,604	14,332	12,671	13,985	18,965	11,174	15,530	17,305	16,249	14,376	14,734
Inventory	1.8%	11,383	11,181	11,198	12,888	12,809	10,268	11,675	11,437	10,990	10,387	10,387	10,100	9,952	9,344	9,599	9,424	8,868	9,020	9,173	9,263	9,086
Net PPE	-1.3%	19,632	19,898	18,821	20,576	20,174	17,982	18,152	18,354	18,701	18,962	18,478	18,632	18,367	18,766	17,855	17,598	17,401	17,658	17,048	17,248	17,000
Goodwill	0.2%	36,616	36,558	36,124	45,440	45,575	36,047	33,383	34,166	34,935	25,436	35,569	35,819	200	36,393	1,200	33,890	200	33,639	33,291	33,661	2,000
Liabilities	3.2%	101,946	98,784	94,833	115,277	125,100	110,574	100,525	101,367	103,646	107,995	108,956	106,860	106,723	111,616	106,220	95,402	93,723	98,257	97,311	94,332	91,072
Current Liabilities	5.3%	48,725	46,282	44,370	54,170	60,373	55,802	45,543	44,821	43,390	45,226	44,561	38,721	40,932	42,493	38,847	36,772	33,689	35,964	35,162	31,353	29,111
Short Term Borrowings	147.8%	8,550	3,451	3,870	11,701	17,979	12,756	4,424	4,305	4,297	3,766	3,798	3,173	3,350	2,631	5,078	5,332	2,190	1,202	2,299	1,719	1,708
Long Term Debt	-3.1%	25,082	25,881	26,051	33,901	34,928	26,886	27,603	28,292	28,851	29,985	30,130	30,310	30,263	32,635	7,500	25,062	25,393	26,494	26,919	27,699	27,660
LT Debt, Non Current	-100.0%	-	25,881	26,051	33,901	34,928	26,886	27,603	28,292	28,851	29,985	30,130	30,310	30,263	32,635	7,500	25,062	25,393	26,494	26,919	27,699	27,660
Shareholder's Equity	1.8%	70,020	68,774	71,228	76,409	70,869	76,804	74,599	76,357	74,709	74,023	70,272	69,580	65,834	63,278	64,473	62,978	61,294	59,471	58,210	60,785	58,955
Retained Earnings	-0.3%	153,378	153,843	152,536	129,381	124,558	128,345	127,917	126,216	124,380	123,060	121,092	120,154	116,508	113,890	114,831	113,898	112,901	110,659	109,242	109,809	106,650
Accumulated Depreciation	0.3%	27,953	27,878	26,805	30,642	30,193	25,552	28,529	28,790	29,001	28,717	28,869	28,569	28,063	28,038	27,307	26,458	25,846	25,674	25,577	25,657	25,262
Shares Outstanding	-4.9%	2,408	2,534	2,523	2,602	2,606	2,625	2,629	2,630	2,629	2,632	2,633	2,632	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	1,260	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	430,000	-	-	-	472,000	-	-	-	445,000	-	-	-	363,000	-	-	-	368,000	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-53.5%	3,657	7,863	7,489	4,182	3,257	5,350	6,284	5,581	3,979	5,732	8,290	5,314	4,074	8,343	8,383	3,452	3,358	6,398	7,527	5,948	3,543
Share Based Compensation	69.7%	302	178	296	382	306	213	281	366	278	215	259	354	307	160	256	326	263	160	245	314	258
Cashflow From Investing	61.4%	-464	-1,202	2,541	-3,776	3,315	-4,397	-1,701	-2,639	-3,634	-5,360	-2,719	-419	-185	-7,903	-4,819	-7,522	-581	-1,344	-1,645	-1,788	-1,417
Cashflow From Financing	111.7%	546	-4,655	-11,317	-5,991	6,138	1,700	-3,925	-2,261	-4,385	-3,436	-2,207	-3,279	-5,125	-5,644	4,196	-357	-4,315	-4,072	-3,893	-4,534	-5,516
Buy Backs	582.9%	1,475	216	920	381	3,537	1,320	2,165	973	1,577	996	391	631	1,438	321	483	706	1,711	426	1,628	2,486	2,206

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

JNJ Income Statement

2024-03-31

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Apr. 02, 2023
Income Statement [Abstract]
Sales to customers (Note 9)	$ 21,383	$ 20,894
Sales to customers percent to sales	100.00%	100.00%
Cost of products sold	$ 6,511	$ 6,687
Cost of products sold percent to sales	30.40%	32.00%
Gross profit	$ 14,872	$ 14,207
Gross Profit Percent To Sales	69.60%	68.00%
Selling, marketing and administrative expenses	$ 5,257	$ 4,906
Selling marketing and administrative expenses percent to sales	24.60%	23.50%
Research and development expense	$ 3,542	$ 3,455
Research and development expense percent to sales	16.60%	16.60%
In-process research and development impairments	$ 0	$ 49
In-process research and development percent to sales	0.00%	0.20%
Interest income	$ (364)	$ (198)
Interest income percent to sales	(1.70%)	(0.90%)
Interest expense, net of portion capitalized	$ 155	$ 212
Interest expense, net of portion capitalized percent to sales	0.70%	1.00%
Other (income) expense, net	$ 2,404	$ 6,940
Other (income) expense, net percent to sales	11.20%	33.20%
Restructuring (Note 12)	$ 164	$ 130
Restructuring charge percent to sales	0.80%	0.60%
Earnings (loss) before provision for taxes on income	$ 3,714	$ (1,287)
Earnings before provision for taxes on income percent to sales	17.40%	(6.20%)
Provision for (benefit from) taxes on income (Note 5)	$ 459	$ (796)
Provision for taxes on income percent to sales	2.20%	(3.90%)
Net earnings (loss) from continuing operations	$ 3,255	$ (491)
Net earnings from continuing operations percent of sales	15.20%	(2.30%)
Net earnings from discontinued operations, net of tax	$ 0	$ 423
Net earnings	$ 3,255	$ (68)
NET EARNINGS PER SHARE
Continuing operations - basic (in dollars per share)	$ 1.35	$ (0.19)
Discontinued operations - basic (in dollars per share)	0	0.16
Total net earnings per share - basic (in dollars per share)	1.35	(0.03)
Continuing operations - diluted (in dollars per share)	1.34	(0.19)
Discontinued operations - diluted (in dollars per share)	0	0.16
Total net earnings per share - diluted (in dollars per share)	$ 1.34	$ (0.03)
Avg. shares outstanding
Basic (shares)	2,408.2	2,605.5
Diluted (shares)	2,430.1	2,605.5

JNJ Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents (Note 4)	$ 25,473	$ 21,859
Marketable securities	745	1,068
Accounts receivable, trade, less allowances $162 (2023, $166)	14,946	14,873
Inventories (Note 2)	11,383	11,181
Prepaid expenses and other	4,455	4,514
Total current assets	57,002	53,495
Property, plant and equipment at cost	47,585	47,776
Less: accumulated depreciation	(27,953)	(27,878)
Property, plant and equipment, net	19,632	19,898
Intangible assets, net (Note 3)	34,286	34,175
Goodwill (Note 3)	36,616	36,558
Deferred taxes on income (Note 5)	10,305	9,279
Other assets	14,125	14,153
Total assets	171,966	167,558
Current liabilities:
Loans and notes payable	8,550	3,451
Accounts payable	8,174	9,632
Accrued liabilities	10,323	10,212
Accrued rebates, returns and promotions	16,182	16,001
Accrued compensation and employee related obligations	2,178	3,993
Accrued taxes on income (Note 5)	3,318	2,993
Total current liabilities	48,725	46,282
Long-term debt (Note 4)	25,082	25,881
Deferred taxes on income (Note 5)	3,172	3,193
Employee related obligations (Note 6)	7,019	7,149
Long-term taxes payable (Note 5)	2,881	2,881
Other liabilities	15,067	13,398
Total liabilities	101,946	98,784
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(10,768)	(12,527)
Retained earnings and Additional paid-in capital	153,378	153,843
Less: common stock held in treasury, at cost (713,120,000 and 712,765,000 shares)	75,710	75,662
Total shareholders’ equity	70,020	68,774
Total shareholders’ equity	70,020	68,774
Total liabilities and shareholders’ equity	$ 171,966	$ 167,558

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

CEO	Mr. Joaquin Duato
WEBSITE	jnj.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	65535

Johnson & Johnson Frequently Asked Questions

What is the ticker symbol for Johnson & Johnson? What does JNJ stand for in stocks?

JNJ is the stock ticker symbol of Johnson & Johnson. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Johnson & Johnson (JNJ)?

As of Thu May 02 2024, market cap of Johnson & Johnson is 360.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JNJ stock?

You can check JNJ's fair value in chart for subscribers.

What is the fair value of JNJ stock?

You can check JNJ's fair value in chart for subscribers. The fair value of Johnson & Johnson is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Johnson & Johnson is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JNJ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Johnson & Johnson a good stock to buy?

The fair value guage provides a quick view whether JNJ is over valued or under valued. Whether Johnson & Johnson is cheap or expensive depends on the assumptions which impact Johnson & Johnson's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JNJ.

What is Johnson & Johnson's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, JNJ's PE ratio (Price to Earnings) is 9.38 and Price to Sales (PS) ratio is 4.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JNJ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Johnson & Johnson's stock?

In the past 10 years, Johnson & Johnson has provided 0.067 (multiply by 100 for percentage) rate of return.